Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers.
- Mechanism
- Curator reviewed · 1 reference
Sipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. This process is done indirectly by the activation of T-cells against PAP which is upregulated by the metastatic cancer cells. The precise mechanism remains unknown, however.
- Primary indication
- Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.Curator reviewed · 2 structured indications
- First approval
- United States, 2010
- Code names
- APC-8015
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Sipuleucel-T, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account